Antigen-specific active immunotherapy for ovarian cancer (Q24240962)

Europe PubMed Central

title

Antigen-specific active immunotherapy for ovarian cancer (English)

0 references

1 reference

1 reference

2

Toos Daemen

0 references

Cornelis J. M. Melief

6

object named as

Kees Melief

0 references

H Marike Boezen

4

object named as

H Marike Boezen

0 references

author name string

Ninke Leffers

1

0 references

Wijnand Helfrich

3

0 references

Ben J Cohlen

5

0 references

Hans W Nijman

Cochrane Database of Systematic Reviews

7

0 references

publication date

20 January 2010

0 references

published in

0 references

cites work

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Novel therapeutic agents in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Evaluating non-randomised intervention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

HER2 Dendritic Cell Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Monoclonal antibodies and idiotypic network activation for ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Antitumor antibodies for immunotherapy of ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021

Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007287.PUB2

7 January 2021